Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Tokyo - Delayed Quote JPY

Human Metabolome Technologies, Inc. (6090.T)

695.00
-1.00
(-0.14%)
At close: 3:30:00 PM GMT+9
Loading Chart for 6090.T
  • Previous Close 696.00
  • Open 696.00
  • Bid 694.00 x --
  • Ask 700.00 x --
  • Day's Range 694.00 - 699.00
  • 52 Week Range 501.00 - 723.00
  • Volume 2,200
  • Avg. Volume 8,993
  • Market Cap (intraday) 4.073B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 15.48
  • EPS (TTM) 44.89
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield 30.00 (4.31%)
  • Ex-Dividend Date Jun 27, 2025
  • 1y Target Est --

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.

www.humanmetabolome.com

58

Full Time Employees

June 30

Fiscal Year Ends

Recent News: 6090.T

View More

Performance Overview: 6090.T

Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

6090.T
13.19%
Nikkei 225 (^N225)
12.60%

1-Year Return

6090.T
7.47%
Nikkei 225 (^N225)
7.15%

3-Year Return

6090.T
19.36%
Nikkei 225 (^N225)
28.64%

5-Year Return

6090.T
32.76%
Nikkei 225 (^N225)
79.46%

Compare To: 6090.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6090.T

View More

Valuation Measures

Annual
As of 4/22/2025
  • Market Cap

    4.08B

  • Enterprise Value

    2.70B

  • Trailing P/E

    15.51

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.95

  • Price/Book (mrq)

    2.12

  • Enterprise Value/Revenue

    1.93

  • Enterprise Value/EBITDA

    6.97

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.97%

  • Return on Assets (ttm)

    6.83%

  • Return on Equity (ttm)

    14.35%

  • Revenue (ttm)

    1.4B

  • Net Income Avi to Common (ttm)

    265M

  • Diluted EPS (ttm)

    44.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.6B

  • Total Debt/Equity (mrq)

    11.32%

  • Levered Free Cash Flow (ttm)

    263.5M

Research Analysis: 6090.T

View More

Company Insights: 6090.T

Research Reports: 6090.T

View More

People Also Watch